CTAD 2023: Roche’s Trontinemab Shows Rapid, Deep Amyloid Clearance Lacking From Gantenerumab

Ongoing Study Will Expand Before Next Trial Begins

 
• By Mandy Jackson
  
3d rendering of human brain on technology background represent artificial intelligence and cyber space concept
Clinical efficacy data, collected as exploratory endpoints, were not reported at CTAD • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D